Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cases in the Management of Metastatic Colorectal Cancer: Rechallenge With Chemotherapy After Regorafenib in a Patient With RAS/BRAF Wild-Type Disease

The third case in a three-part series, this article chronicles the treatment journey of a 50-year-old male patient who had been diagnosed with left-sided colon cancer in January 2016. After multiple FOLFOX doses, FOLFIRI cycles, and resection, the patient began treatment with regorafenib in July 2020 as a third-line treatment, with the hope that this agent could potentially re-sensitize the tumor to subsequent anti–epidermal growth factor receptor (EGFR) therapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form